Empagliflozin for treating chronic heart failure with reduced ejection fraction
KEYWORDS: empagliflozin, heart, heart failure, failure, treatment, committee, people, care, dapagliflozin, reduced, fraction, ejection fraction, ejection, standard care, reduced ejection

mainly included people with a white family background. The committee noted that neither EMPEROR-Reduced or DAPA-HF was powered to show difference between subgroups of different ages or people from a different family background. The clinical experts said that there is no reason to restrict empagliflozin use in adults based on age or family background. The committee noted that its recommendations applied to all people regardless of family background. It recognised that there were no ongoing clinical trials or data collection to validate the possibility of differences in treatment effect because of family background. But it considered that there may be the potential to explore this issue further in future research. A heart failure specialist should advise on starting empagliflozin and the most appropriate healthcare professional should monitor treatment 3.11 NICE's guideline on chronic heart failure in adults: diagnosis and management recommends that a specialist heart failure multidisciplinary team should work in collaboration with the primary care team to start new medicines that need specialist supervision. The committee noted that people taking empagliflozin for heart failure who also have diabetes might need adjustments in their diabetes medication for safety reasons because of an increased risk of ketoacidosis. The committee considered that
